🇺🇸 FDA
Patent

US 6984379

Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood

expired A61KA61K38/50A61K48/0008

Quick answer

US patent 6984379 (Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 10 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/50, A61K48/0008